AU2015286199B2 - Methods for the treatment of hepatitis B and hepatitis D virus infections - Google Patents

Methods for the treatment of hepatitis B and hepatitis D virus infections Download PDF

Info

Publication number
AU2015286199B2
AU2015286199B2 AU2015286199A AU2015286199A AU2015286199B2 AU 2015286199 B2 AU2015286199 B2 AU 2015286199B2 AU 2015286199 A AU2015286199 A AU 2015286199A AU 2015286199 A AU2015286199 A AU 2015286199A AU 2015286199 B2 AU2015286199 B2 AU 2015286199B2
Authority
AU
Australia
Prior art keywords
hbv
pharmaceutically acceptable
nucleic acid
seq
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015286199A
Other languages
English (en)
Other versions
AU2015286199A1 (en
Inventor
Andrew Vaillant
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Replicor Inc
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015286199(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of AU2015286199A1 publication Critical patent/AU2015286199A1/en
Application granted granted Critical
Publication of AU2015286199B2 publication Critical patent/AU2015286199B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AU2015286199A 2014-07-10 2015-07-07 Methods for the treatment of hepatitis B and hepatitis D virus infections Ceased AU2015286199B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US62/022,846 2014-07-10
US201462091943P 2014-12-15 2014-12-15
US62/091,943 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Publications (2)

Publication Number Publication Date
AU2015286199A1 AU2015286199A1 (en) 2017-02-23
AU2015286199B2 true AU2015286199B2 (en) 2020-05-14

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015286199A Ceased AU2015286199B2 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis B and hepatitis D virus infections

Country Status (34)

Country Link
US (1) US9603865B2 (https=)
EP (1) EP3166615B1 (https=)
JP (2) JP2017521433A (https=)
KR (2) KR20170029577A (https=)
CN (2) CN106659730A (https=)
AU (1) AU2015286199B2 (https=)
BR (1) BR112017000320B1 (https=)
CA (1) CA2954182C (https=)
CL (1) CL2017000008A1 (https=)
CU (1) CU20170001A7 (https=)
CY (1) CY1126361T1 (https=)
DK (1) DK3166615T3 (https=)
DO (1) DOP2017000002A (https=)
EA (1) EA036745B1 (https=)
EC (1) ECSP16097355A (https=)
ES (1) ES2963814T3 (https=)
FI (1) FI3166615T3 (https=)
HK (1) HK1231402A1 (https=)
HR (1) HRP20231400T1 (https=)
HU (1) HUE064449T2 (https=)
IL (1) IL249660B (https=)
LT (1) LT3166615T (https=)
MD (1) MD4760C8 (https=)
MX (1) MX381042B (https=)
MY (1) MY178087A (https=)
PH (1) PH12017500010B1 (https=)
PL (1) PL3166615T3 (https=)
PT (1) PT3166615T (https=)
RS (1) RS64833B1 (https=)
SG (1) SG11201700073PA (https=)
SI (1) SI3166615T1 (https=)
SM (1) SMT202300380T1 (https=)
TW (1) TWI766831B (https=)
WO (1) WO2016004525A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211783A1 (es) * 2018-11-08 2021-09-08 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos
US11166976B2 (en) * 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN113620993A (zh) * 2020-05-07 2021-11-09 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦d晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
JP2024527380A (ja) 2021-07-09 2024-07-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド 腎機能障害を有する個体へのオリゴヌクレオチドの使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170386A1 (en) * 2012-05-18 2013-11-21 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
WO2014032176A1 (en) * 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
BR0314236A (pt) 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
US9474793B2 (en) * 2005-02-22 2016-10-25 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
BR112013003875B1 (pt) 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
WO2012058210A1 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170386A1 (en) * 2012-05-18 2013-11-21 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
WO2014032176A1 (en) * 2012-08-30 2014-03-06 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d infections

Also Published As

Publication number Publication date
LT3166615T (lt) 2024-01-25
MY178087A (en) 2020-10-02
EA201790160A1 (ru) 2017-06-30
WO2016004525A1 (en) 2016-01-14
MD4760B1 (ro) 2021-07-31
KR20230070330A (ko) 2023-05-22
BR112017000320A2 (pt) 2017-11-07
US9603865B2 (en) 2017-03-28
HRP20231400T1 (hr) 2024-02-16
MX381042B (es) 2025-03-12
PH12017500010A1 (en) 2017-05-15
RS64833B1 (sr) 2023-12-29
DK3166615T3 (da) 2023-11-13
NZ727583A (en) 2024-08-30
EP3166615A1 (en) 2017-05-17
JP2017521433A (ja) 2017-08-03
KR20170029577A (ko) 2017-03-15
MD20170014A2 (ro) 2017-07-31
MX2017000053A (es) 2017-05-01
CN106659730A (zh) 2017-05-10
HUE064449T2 (hu) 2024-03-28
EP3166615A4 (en) 2018-01-17
JP6922030B2 (ja) 2021-08-18
SMT202300380T1 (it) 2024-01-10
ECSP16097355A (es) 2017-03-31
CN113750112A (zh) 2021-12-07
EP3166615B1 (en) 2023-08-09
MD4760C8 (ro) 2022-02-28
ES2963814T3 (es) 2024-04-02
JP2020143065A (ja) 2020-09-10
IL249660A0 (en) 2017-02-28
CA2954182C (en) 2023-08-15
PL3166615T3 (pl) 2024-02-19
PT3166615T (pt) 2023-11-13
DOP2017000002A (es) 2017-03-15
CU20170001A7 (es) 2017-04-05
IL249660B (en) 2022-02-01
US20160008393A1 (en) 2016-01-14
CL2017000008A1 (es) 2017-06-09
TWI766831B (zh) 2022-06-11
FI3166615T3 (fi) 2023-11-06
PH12017500010B1 (en) 2022-07-29
TW201613617A (en) 2016-04-16
BR112017000320B1 (pt) 2023-02-07
KR102734495B1 (ko) 2024-11-25
AU2015286199A1 (en) 2017-02-23
EA036745B1 (ru) 2020-12-16
SI3166615T1 (sl) 2023-12-29
HK1231402A1 (zh) 2017-12-22
CA2954182A1 (en) 2016-01-14
CY1126361T1 (el) 2026-02-25
SG11201700073PA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
AU2015286199B2 (en) Methods for the treatment of hepatitis B and hepatitis D virus infections
KR102918289B1 (ko) B형 간염 바이러스 (HBV) dsRNA 제제 조성물 및 이의 사용 방법
CN104837501B (zh) 治疗乙型肝炎及丁型肝炎感染的方法
CN112933085A (zh) 一种化合物在制备治疗或预防病毒性肝炎用药物中的应用
CN114432351A (zh) 老鹳草有效成分用于治疗或预防病毒性肝炎的应用
HK40065449A (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
CN115337310A (zh) 一种抗炎剂在制备治疗或预防病毒性肝炎药物的应用
CN114224888B (zh) 兰索拉唑在制备治疗或预防病毒性肝炎用药物中的用途
CN115245569A (zh) 一种用于治疗病毒性肝炎的药物组合物
CN114948949A (zh) Hsp90抑制剂用于治疗或预防病毒性肝炎的应用
CN114533743A (zh) 一种用于治疗或预防病毒性肝炎的药物组合物
CN116173219A (zh) 一种用于治疗病毒性肝炎的药物组合物
CN114053293A (zh) 杂环基化合物在制备治疗或预防病毒性肝炎药物中的应用
CN114073702A (zh) 喹诺酮类化合物在治疗或预防乙型肝炎中的应用
EA048263B1 (ru) КОМПОЗИЦИИ АГЕНТОВ дцРНК ВИРУСА ГЕПАТИТА B (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
OA20174A (en) Hepatitis B Virus (HBV) dsRNA Agent Compositions And Methods Of Use Thereof
OA21432A (en) Hepatitis b virus (HBV) dsRNA agent compositions and methods of use thereof.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired